A Systematic Review of the Efficacy of Preclinical Models of Lung Cancer Drugs
Background: Preclinical cell models are the mainstay in the early stages of drug development. We sought to explore the preclinical data that differentiated successful from failed therapeutic agents in lung cancer.Methods: One hundred thirty-four failed lung cancer drugs and twenty seven successful l...
Main Authors: | Elizabeth Pan, David Bogumil, Victoria Cortessis, Sherrie Yu, Jorge Nieva |
---|---|
Format: | Article |
Language: | English |
Published: |
Frontiers Media S.A.
2020-04-01
|
Series: | Frontiers in Oncology |
Subjects: | |
Online Access: | https://www.frontiersin.org/article/10.3389/fonc.2020.00591/full |
Similar Items
-
Generation and Characterization of a New Preclinical Mouse Model of EGFR-Driven Lung Cancer with MET-Induced Osimertinib Resistance
by: Maicol Mancini, et al.
Published: (2021-07-01) -
Current status and evolution of preclinical drug development models of epithelial ovarian cancer
by: Panagiotis A Konstantinopoulos, et al.
Published: (2013-12-01) -
Development of syngeneic murine cell lines for use in immunocompetent orthotopic lung cancer models
by: Kyle Nolan, et al.
Published: (2020-08-01) -
Tumor regression mediated by oncogene withdrawal or erlotinib stimulates infiltration of inflammatory immune cells in EGFR mutant lung tumors
by: Deborah Ayeni, et al.
Published: (2019-07-01) -
Meta-Analysis of Preclinical Studies of Fibrinolytic Therapy for Acute Lung Injury
by: Cong Liu, et al.
Published: (2018-08-01)